The Influences of COVID-19 on Stromectol Treatment

The new stromectol treatment presented on https://pocketdrugguide.com/antiparasitic/stromectol-the-invention-uses-and-dosages.html depends on the severity of the disease and the response to treatment, based on our experience in treating patients. In the final part, an assessment of the benefit-risk ratio when using Ivermectin is given, and it is concluded that, since there is practically no risk of risk during its use, it is recommended to include the drug in the first line of therapy for COVID-19.

Stromectol is an FDA-approved antiparasitic drug that is regarded as an essential drug by WHO and has been widely used worldwide for almost 40 years. Until 2008, about 2,000 million tablets had been administered to 68 million patients in Africa, Latin America, and Yemen, thereby eradicating onchocerciasis. In 2009, the WHO viewed drug therapy as a “triumph in treatment”. The drug is widely used in human therapy, it is not an experimental drug, it is not patented, it is widely available, has a high safety profile, is very well tolerated at a standard dose of 200 mcg/kg, and no adverse events have been reported at a dose of two times higher than usual (1,2,3). Thus, we have extensive experience in the use of the drug in the absence of toxicity.

The existing assumption regarding the benefits of using Ivermectin in COVID-19 has been revised. The study, recently published in the journal Antiviral Research, was conducted with patients from 169 hospitals around the world. Ivermectin therapy was prescribed to 704 patients, a group of 704 more patients constituted the control. The results of the study showed that the number of deaths in patients taking Ivermectin was 6.1 times less than in patients who did not receive Ivermectin (1.4% versus 8.5%, p <0.0001).